Mineralys Therapeutics (MLYS) News Today → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free MLYS Stock Alerts $12.77 +0.35 (+2.82%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 5:37 AM | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Purchased by Franklin Resources Inc.Franklin Resources Inc. boosted its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 55.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 699,467 shares of the company's stock after purchasing an additional 249,450 shares during the period.May 13, 2024 | markets.businessinsider.comBank of America Securities Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)May 13, 2024 | finance.yahoo.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call TranscriptMay 10, 2024 | markets.businessinsider.comMineralys Therapeutics: Strong Buy on Upcoming ADVANCE Trial Results and Robust Financial HealthMay 10, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 4.6%Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 4.6%May 9, 2024 | msn.comMineralys Therapeutics GAAP EPS of -$0.70 misses by $0.03May 9, 2024 | globenewswire.comMineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 6, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Sees Unusually-High Trading VolumeMineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading VolumeMay 6, 2024 | globenewswire.comMineralys Therapeutics to Participate in the Bank of America Securities Health Care ConferenceMay 3, 2024 | marketbeat.comMineralys Therapeutics (MLYS) to Release Quarterly Earnings on ThursdayMineralys Therapeutics (NASDAQ:MLYS) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 3, 2024 | msn.comMineralys Therapeutics to Unveil First Quarter Financial ResultsMay 2, 2024 | globenewswire.comMineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024April 18, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Down 3.7% Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 3.7%April 2, 2024 | msn.comGoldman starts Mineralys at buy, cites upcoming drug dataApril 2, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Coverage Initiated at The Goldman Sachs GroupThe Goldman Sachs Group initiated coverage on Mineralys Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $30.00 target price on the stock.March 28, 2024 | marketbeat.comAnalysts Issue Forecasts for Mineralys Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:MLYS)Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Stock analysts at Lifesci Capital issued their FY2024 earnings estimates for Mineralys Therapeutics in a research note issued to investors on Tuesday, March 26th. Lifesci Capital analyst R. Katkhuda expects that the company will earn ($2.March 28, 2024 | marketbeat.comLifesci Capital Reiterates Outperform Rating for Mineralys Therapeutics (NASDAQ:MLYS)Lifesci Capital reissued an "outperform" rating on shares of Mineralys Therapeutics in a research report on Tuesday.March 27, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up to $12.84Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up to $12.84March 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic DevelopmentsMarch 22, 2024 | finance.yahoo.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | msn.comMineralys Therapeutics files for $500M mixed shelf offeringMarch 21, 2024 | finance.yahoo.comMineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...March 21, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Trading Down 4.7%Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 4.7%March 21, 2024 | seekingalpha.comMineralys Therapeutics, Inc. 2023 Q4 - Results - Earnings Call PresentationMarch 21, 2024 | globenewswire.comMineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 20, 2024 | finance.yahoo.comMLYS Jun 2024 12.500 callMarch 20, 2024 | finance.yahoo.comMLYS Sep 2024 30.000 callMarch 20, 2024 | benzinga.comMineralys Therapeutics Earnings PreviewMarch 19, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Up 4.7%Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 4.7%March 18, 2024 | msn.comMineralys Therapeutics Set to Release Q4 and Full-Year 2023 Financial Results, Eyes on Future Growth ProspectsMarch 18, 2024 | seekingalpha.comMineralys Therapeutics: A Story To Keep An Eye OnMarch 16, 2024 | finance.yahoo.comMLYS Apr 2024 15.000 callMarch 16, 2024 | finance.yahoo.comMLYS Mar 2024 20.000 callMarch 13, 2024 | globenewswire.comMineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024March 9, 2024 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Acquired by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC increased its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 64.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 192,362 sharesMarch 7, 2024 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Position Increased by Fmr LLCFmr LLC increased its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 62.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,188,653 shares of the company's stock after buyMarch 4, 2024 | benzinga.comMineralys Therapeutics Stock (NASDAQ:MLYS) Dividends: History, Yield and DatesMarch 1, 2024 | marketbeat.comBraidwell LP Purchases 1,473,600 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Braidwell LP grew its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 267.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,023,900 shares of the company's stock after purchasing an additional 1,473,60February 9, 2024 | seekingalpha.comMineralys: 2nd Half 2024 Hypertension Data ReadoutFebruary 9, 2024 | bizjournals.comMineralys Therapeutics set to raise $120M from investors to develop treatment for high blood pressureFebruary 9, 2024 | msn.comMineralys Therapeutics Equity Sales: Investor Impact ReportFebruary 9, 2024 | msn.comMineralys Therapeutics Announces Strategic Purchase AgreementFebruary 8, 2024 | msn.comMineralys Therapeutics stock jumps on $120M private placement financingFebruary 8, 2024 | finance.yahoo.comMineralys Therapeutics Announces $120 Million Private Placement FinancingFebruary 2, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up to $12.70Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up to $12.70January 30, 2024 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Sees Large Decrease in Short InterestMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 836,900 shares, a decrease of 15.5% from the December 31st total of 990,600 shares. Based on an average daily trading volume, of 173,200 shares, the short-interest ratio is presently 4.8 days. Approximately 4.4% of the company's shares are sold short.January 29, 2024 | finance.yahoo.comMineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology ConferenceJanuary 17, 2024 | finance.yahoo.comMineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should KnowJanuary 6, 2024 | seekingalpha.comMLYS Mineralys Therapeutics, Inc.January 4, 2024 | finance.yahoo.comMineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address LEAKED: Jeff Bezos' $330 Million Gamble (Ad)Did you know that 3 simple words are disrupting a $62.7 billion market? "Blood Brain Barrier" Seems innocent enough. Here's how you could invest alongside them >>> MLYS Media Mentions By Week MLYS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLYS News Sentiment▼1.890.76▲Average Medical News Sentiment MLYS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLYS Articles This Week▼21▲MLYS Articles Average Week Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ARVN News Today BHC News Today RYTM News Today DCPH News Today AGIO News Today AMRX News Today AMPH News Today VERA News Today GERN News Today CPRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLYS) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceBill Clinton Backing Biden Replacement???The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.